Ipamorelin

At a glance

What is ipamorelin?

Ipamorelin is a fully synthetic pentapeptide — a chain of just 5 amino acids — that mimics ghrelin, the body's "hunger hormone." It binds to the same receptor on pituitary cells (GHS-R1a, the ghrelin receptor), triggering them to release growth hormone.^[1]

The compound was developed by Novo Nordisk in Denmark in the mid-1990s, emerging from a systematic effort to create growth hormone-releasing peptides with fewer side effects than earlier compounds. The name "ipamorelin" is a research designation — it was never given a brand name because it never reached the market.

What makes ipamorelin notable is its selectivity. Older growth hormone secretagogues like GHRP-6 and GHRP-2 work, but they also raise cortisol (the stress hormone), prolactin, and aldosterone as collateral effects. Ipamorelin does not — even at extremely high doses. In the original 1998 characterization, the researchers titled their paper "Ipamorelin, the first selective growth hormone secretagogue," and that selectivity has been confirmed in subsequent studies.^[1]

Later, Helsinn Therapeutics licensed ipamorelin and attempted to develop it for a specific medical application: postoperative ileus (the temporary paralysis of gut motility after abdominal surgery). The rationale was sound — ghrelin receptor agonism promotes GI motility — but the Phase II trial failed to show significant efficacy, and development was discontinued.^[6]

How it works

In plain terms, ipamorelin tricks the pituitary gland into releasing a pulse of growth hormone by mimicking ghrelin — the natural signal that triggers GH release. That pulse then travels through the body, stimulating the liver to produce IGF-1, which mediates many of GH's downstream effects: protein synthesis, lipolysis (fat breakdown), and bone turnover.

The key difference from injecting growth hormone directly: ipamorelin works through the body's own regulatory system, preserving the natural pulsatile pattern of GH release and the feedback loops that prevent excess.

What the research says

Ipamorelin's selectivity is the most well-supported claim in its profile. Its efficacy for anything clinically meaningful in humans is not. The compound failed its only completed efficacy trial, and the outcomes people actually want — fat loss, muscle gain, better sleep — have never been studied.

Research timeline

Ipamorelin's research history is unusually corporate — nearly all data comes from Novo Nordisk (who developed it) and Helsinn (who tried to bring it to market). When the clinical program failed, academic interest largely stopped.

Human clinical trials

The entire body of published human data for ipamorelin consists of Phase I pharmacology studies and one Phase II efficacy trial. Here's what each found:

What's missing: There are zero published human trials for body composition, fat loss, muscle gain, sleep quality, anti-aging, or any of the outcomes that ipamorelin is most commonly marketed for. The Phase II program tested it for gut motility, not physique enhancement — and it failed.^[6]

That has not changed. We re-searched PubMed and ClinicalTrials.gov in August 2026: no new human trial of ipamorelin exists — none completed, none recruiting, none registered. The single registry record that mentions ipamorelin is an observational study of a different intervention entirely, in which ipamorelin appears as one item in an unblinded supplement stack alongside testosterone and other hormones. It is not a trial of ipamorelin and should not be cited as one.

Animal studies

The preclinical data is primarily from Novo Nordisk's development program and supports the selectivity profile:

What the evidence shows

People come to ipamorelin with specific goals. Here's what the published research actually supports — and where the evidence runs out:

Safety & side effects

What research shows

Ipamorelin has better safety data than many unregulated peptides — the Phase II trial provides tolerability data from 114 participants, which is substantially more than most compounds in this space. At 0.03 mg/kg BID for up to 7 days, ipamorelin was well-tolerated with side effects comparable to placebo.^[6]

However, this safety data covers a very specific context: IV infusion in hospitalized post-surgical patients over 7 days. It tells us nothing about the safety of long-term subcutaneous use for body composition goals — which is how most people actually use it.

What the FDA has said

There is a harder fact that sits alongside the tolerability data, and it is now published in the FDA's own words. In the safety rationale accompanying its bulk-substance categories — page content current as of April 22, 2026 — the FDA writes:^[11]

A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.

We are not softening that, and we are also not overstating it. Three points of context, all of which matter:

• Causality is not established. FDA describes adverse events observed in study subjects. It does not claim ipamorelin caused the deaths, and neither do we.
• The setting was intravenous administration for gastric motility — the same clinical program described above, the one Helsinn discontinued. The trial that produced ipamorelin's largest tolerability dataset and the signal that concerned the FDA come from the same body of work.
• This is why ipamorelin is restricted. Reporting in April 2026 established that FDA's 2023 category decisions across six peptides — GHRP-2, ibutamoren, ipamorelin, CJC-1295, AOD-9604 and melanotan II — rested on documented immunogenicity risk and adverse events including deaths with causality unestablished.^[13]

A reasonable person can read this and still conclude that subcutaneous ipamorelin at community doses is unlikely to kill them. What a reasonable person cannot do is claim ipamorelin has a clean safety record. The regulator that reviewed the underlying data does not think so, and it has said why in public.

A 2026 review in Sports Medicine covering ipamorelin and the other GH-axis peptides reaches a compatible conclusion: favorable animal data, scarce rigorous human safety data, real potential for serious harm.^[14]

Clinical trial side effects

From the Phase II data, reported effects were minimal:

• Injection-site reactions
• Mild headache
• Transient nausea or lightheadedness
• Facial flushing

Community-reported side effects

Among people using ipamorelin outside of clinical settings, commonly reported effects include:

• Water retention and bloating
• Tingling or numbness in hands (carpal tunnel-like symptoms)
• Increased hunger (less than GHRP-6, but reported)
• Vivid dreams or disrupted sleep
• Transient fatigue
• Flushing after injection

These are self-reported and not from controlled studies. Product quality in the gray market introduces additional confounders.

Theoretical risks

How people use it

Ipamorelin is most commonly used in the anti-aging and body composition community as a growth hormone secretagogue — often combined with CJC-1295. Here's what the landscape of use looks like, with important context about what is and isn't supported by evidence.

Administration route

• Subcutaneous injection (most common): Injected in the abdomen, thigh, or upper arm.
• The Phase II clinical trial used intravenous infusion — a different route than how most people use it. No published data exists on subcutaneous pharmacokinetics.

The CJC-1295 + Ipamorelin combination

This is the most popular way ipamorelin is used in practice. The rationale:

• CJC-1295 is a GHRH analog — it acts on the GHRH receptor to amplify GH pulse amplitude and extend its duration.
• Ipamorelin is a ghrelin mimetic — it acts on the GHS-R1a receptor to initiate GH pulses.
• Together, they target two different pathways, which is pharmacologically plausible for additive or synergistic GH release.

This combination is often described as the "entry-level" GH secretagogue stack in the peptide community. It was widely available through telehealth peptide clinics before the 2023 FDA restrictions.

Worth knowing: both halves of this stack carry FDA safety language. For ipamorelin, serious adverse events including death with intravenous use. For CJC-1295, increased heart rate and systemic vasodilatory reaction. Neither statement establishes causality, and neither describes the subcutaneous doses used in practice — but the pairing is not two compounds with clean records.

The evidence gap: Despite being the most commonly prescribed peptide combination in the U.S. anti-aging market, the CJC-1295 + ipamorelin stack has never been tested in a controlled human trial. Not once. The pairing is based entirely on mechanistic reasoning and clinical observation — reasonable, but not proven.

Legal & regulatory status

As of August 2026:

FDA status

Ipamorelin is not FDA-approved for any indication. Its regulatory history is a winding path, and it is very commonly reported wrong — including, until this update, on this page:

• September 29, 2023: FDA placed ipamorelin acetate on the Category 2 list — bulk substances that may present significant safety risks when used in compounding.^[11]
• September 2024: The 503A nomination was withdrawn by the party who submitted it. Ipamorelin acetate moved into FDA's separate "nominated but withdrawn" table on the 503A side only.
• 2024: The Pharmacy Compounding Advisory Committee (PCAC) voted against recommending ipamorelin for the 503A bulks list.
• April 22, 2026: The most recent update to FDA's category page. Ipamorelin acetate is still in the active Category 2 table under the 503B interim policy.

FDA has also said that, going forward, it does not intend to place substances nominated on or after January 7, 2025 into categories 1, 2 or 3 at all. Category language is therefore a description of a legacy process, not a permanent framework.

Separately, law-firm reporting of FDA's filings in litigation brought by compounding interests describes an agreement to expedite review of ipamorelin acetate, CJC-1295, AOD-9604 and thymosin alpha-1, with a final rule stated as due no later than March 14, 2027. We have not verified that timeline against the court docket, so treat it as reported rather than confirmed. Whatever comes of it, a category change would not be FDA approval — it would only govern whether a pharmacy may compound with the substance.

WADA / USADA status

Ipamorelin is prohibited at all times under WADA Section S2, specifically named under S2.2.4 (growth hormone releasing factors) in the bullet covering growth hormone secretagogues and their mimetics.^[12]

All S2 substances are non-Specified, which generally means a heavier starting sanction — up to four years — though the actual outcome depends on the athlete's ability to establish how the substance entered their system and whether the violation was intentional. Sanctions vary; four years is the ceiling, not an automatic result.

International status

Ipamorelin is not approved for clinical use in any country. Helsinn Therapeutics discontinued development after the postoperative ileus trials failed, and no company has picked it up since. It is available as a "research chemical" in most jurisdictions.

How ipamorelin compares

To understand ipamorelin's place in the peptide landscape, here's how it compares to CJC-1295 — the compound it's most commonly paired with:

The key insight: these compounds act on different receptors and are often presented as complementary. Ipamorelin initiates the GH pulse (via the ghrelin receptor); CJC-1295 amplifies it (via the GHRH receptor). Together, the theory is a larger, more sustained GH release. Neither compound has strong human efficacy data on its own, and the combination has never been studied in a controlled trial.